[PDF][PDF] Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
…, M Ennis, KI Pritchard, ME Trudeau… - Journal of clinical …, 2002 - academia.edu
Purpose: Insulin, a member of a family of growth factors that includes insulin-like growth factor
(IGF)-I and IGF-II, exerts mitogenic effects on normal and malignant breast epithelial cells, …
(IGF)-I and IGF-II, exerts mitogenic effects on normal and malignant breast epithelial cells, …
[HTML][HTML] Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer
…, DR McCready, LA Manchul, ME Trudeau… - … England Journal of …, 2004 - Mass Medical Soc
Background We determined the effect of breast irradiation plus tamoxifen on disease-free
survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative …
survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative …
[HTML][HTML] Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens …
…, N Masuda, M Palacova, ME Trudeau… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
METHODS Patients, including those with stable, asymptomatic CNS disease, were randomly
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
[HTML][HTML] Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
…, A Awada, L Garcia-Estevez, ME Trudeau… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. …
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. …
Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations
…, M Ennis, KI Pritchard, ME Trudeau… - Journal of clinical …, 2012 - ascopubs.org
Purpose To investigate patterns of prognostic associations over time of insulin- and obesity-related
variables measured at diagnosis of early breast cancer (BC), focusing on whether the …
variables measured at diagnosis of early breast cancer (BC), focusing on whether the …
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
…, J Cortes, A Awada, CM Kelly, ME Trudeau… - 2015 - ascopubs.org
1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC.
ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate …
ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate …
Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update
…, AH Partridge, MR Somerfield, ME Trudeau… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To update key recommendations of the ASCO guideline adaptation of the Cancer
Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early …
Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early …
Neratinib+ capecitabine versus lapatinib+ capecitabine in patients with HER2+ metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Findings …
…, WJ Gradishar, N Masuda, M Palacova, ME Trudeau… - 2019 - ascopubs.org
1002 Background: NALA (ClinicalTrials.gov NCT01808573) is a multinational, randomized,
open-label, phase III trial of neratinib (an irreversible pan-HER tyrosine kinase inhibitor [TKI]) …
open-label, phase III trial of neratinib (an irreversible pan-HER tyrosine kinase inhibitor [TKI]) …
Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update
PURPOSE The aim of this work is to update key recommendations of the ASCO guideline
adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant …
adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant …
Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)–negative and adjuvant targeted therapy for HER2 …
…, AH Partridge, ML Telli, ME Trudeau… - Journal of Clinical …, 2016 - ascopubs.org
Purpose A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant
chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human …
chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human …